Amy S. Clark, MD, MSCE

faculty photo
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.

Description of Research Expertise

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications

Lynce, F., Stevens, L. E., Li, Z., Brock, J. E., Gulvady, A., Huang, Y., Nakhlis, F., Patel, A., Force, J. M., Haddad, T. C., Ueno, N., Stearns, V., Wolff, A. C., Clark, A. S., Bellon, J. R., Richardson, E. T., Balko, J. M., Krop, I. E., Winer, E. P., Lange, P., Hwang E. S., King, T. A., Tolaney, S. M., Thompson, A., Gupta, G. P., Mittendorf, E. A., Regan, M. M., Overmoyer, B., Polyak, K: TBCRC 039: A phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Research January 2024.

Albain K, Yau C, Petricoin E, Wolf D, Lang J, Chien A, Haddad T, Forero-Torres A, Wallace A, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias A, Clark A, Godellas C, Boughey J, Isaacs C, Tripathy D, Lu J, Yung R, Gallagher R, Wulfkuhle J, Swigart LB, Krings G, Chen YY, Potter D, Stringer-Reasor E, Blair S, Asare S, Wilson A, Hirst G, Singhrao R, Buxton M, Clennell J, Sanil A, Berry S, Asare A, Matthews J, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans W, Van't Veer L, Yee D, Berry D, Esserman L: Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial — Efficacy and biomarker discovery. Clinical Cancer Research January 2024 Notes: Under Review

Zhang, H., Clark, A.S., : A quantitative bias analysis approach to informative presence bias in electronic health records. Epidemiology 2023; In Press.

Fraietta J, Fengjuan Z, Clark A, Taunk N, Xu H N, Gonzalves D, Ahmad Z, Minn A, Huang A, Nayak A, Tchou J: A high pre-existing TCR repertoire diversity may predict response to preoperative radiotherapy and pembrolizumab in early-stage breast cancer –NCT04454528 preliminary results. Society of Surgical Oncology 2023, in press.

Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chein AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edminston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele A, Van't Veer LJ, Esserman LJ, Olopade OI: Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Network Open Dec 2023.

Amy S. Clark.: "NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET)". San Antonio Breast Cancer Symposium BR009 Spotlight, San Antonio, TX. Dec 2023 Notes: "Oral Presentation"

Ulaner GA, Fowler AM, Clark AS, Linden H: Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer. PET Clin 18(4): 531-542, Oct 2023.

Amy Sanders Clark, Fengmin Zhao, Paula Klein, Alberto J. Montero, Carla Isadora Falkson, Elisa Krill-Jackson.: "BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab". The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium, ASCO Annual Meeting, Chicago, IL. Jun 2023 Notes: "Oral Presentation"

Haddad TC, Suman VJ, D’ Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Young SO, Clark AS, Ingrid AM, Keyomarsi K, Hobday TJ, Peethambaram PP, O’Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. : Phase II Trial of Alisertib Alone or Combined with Fulvestrant in Endocrine-resistant, Advanced Breast Cancer (TBCRC 041). JAMA Oncology 9(6): 815-824, Jun 2023.

Martei Y M, Chen K, Mamtani R, Shulman L N, Hubbard R A, Clark A: Racial disparities in utilization of first line targeted therapies for metastatic breast cancer. J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL. 41(16), Jun 2023 Notes: "Poster Presentation"

back to top
Last updated: 02/14/2024
The Trustees of the University of Pennsylvania